Guiding the way

George Church's Harvard Medical School lab is addressing head-on one of the biggest limitations of CRISPR-based gene editing: Until the tech has been proven to cut only where and when needed, it won't make the jump from useful lab tool to human therapy.

In a study published last month in Nature Methods, the group presented a computational tool designed to increase the odds of generating reagents that are both safe and efficient...